Bremelanotide acetate - Generic Drug Details

✉ Email this page to a colleague

What are the generic drug sources for bremelanotide acetate and what is the scope of freedom to operate?

Bremelanotide acetate is the generic ingredient in one branded drug marketed by Cosette and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Bremelanotide acetate has eighty-one patent family members in twenty-six countries.

One supplier is listed for this compound.

Summary for bremelanotide acetate

International Patents:	81
US Patents:	5
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	1
DailyMed Link:	bremelanotide acetate at DailyMed

Recent Clinical Trials for bremelanotide acetate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Palatin Technologies, Inc	Phase 2

See all bremelanotide acetate clinical trials

Pharmacology for bremelanotide acetate

Drug Class	Melanocortin Receptor Agonist
Mechanism of Action	Melanocortin Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for bremelanotide acetate

G02CX	Other gynecologicals
G02C	OTHER GYNECOLOGICALS
G02	OTHER GYNECOLOGICALS
G	Genito-urinary system and sex hormones

US Patents and Regulatory Information for bremelanotide acetate

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cosette	VYLEESI (AUTOINJECTOR)	bremelanotide acetate	SOLUTION;SUBCUTANEOUS	210557-001	Jun 21, 2019		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Cosette	VYLEESI (AUTOINJECTOR)	bremelanotide acetate	SOLUTION;SUBCUTANEOUS	210557-001	Jun 21, 2019		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Cosette	VYLEESI (AUTOINJECTOR)	bremelanotide acetate	SOLUTION;SUBCUTANEOUS	210557-001	Jun 21, 2019		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for bremelanotide acetate

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cosette	VYLEESI (AUTOINJECTOR)	bremelanotide acetate	SOLUTION;SUBCUTANEOUS	210557-001	Jun 21, 2019	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for bremelanotide acetate

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Eurasian Patent Organization	032959	ПРИМЕНЕНИЕ БРЕМЕЛАНОТИДА В ТЕРАПИИ ЖЕНСКОЙ СЕКСУАЛЬНОЙ ДИСФУНКЦИИ (USES OF BREMELANOTIDE IN THERAPY FOR FEMALE SEXUAL DYSFUNCTION)	⤷ Sign Up
Australia	2005249474		⤷ Sign Up
Japan	2008505917		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.